Table 1.
Characteristics | Overall survival | |||
---|---|---|---|---|
N (%)* | N of deaths* | 5-year survival rate, % | P† | |
All patients | 188 | 61 | 69.3 | |
Age, years | ||||
Median (IQR) | 65 (54-73) | |||
<65 | 90 (47.9) | 30 | 67.6 | 0.823 |
≥65 | 98 (52.1) | 31 | 70.9 | |
Gender | ||||
Male | 97 (51.6) | 37 | 63.4 | 0.092 |
Female | 91 (48.4) | 24 | 75.6 | |
CEA, μg/L | ||||
Median (IQR) | 4.6 (1.8-14.4) | |||
<5 | 89 (51.4) | 13 | 86.4 | <0.001 |
≥5 | 84 (48.6) | 40 | 53.9 | |
Differentiation | ||||
Well | 39 (22.0) | 10 | 74.0 | 0.147 |
Moderate | 117 (66.1) | 38 | 69.6 | |
Poor | 21 (11.9) | 10 | 52.4 | |
Stage‡ | ||||
I-III | 152 (81.3) | 36 | 78.2 | <0.001 |
IV | 35 (18.7) | 25 | 29.8 | |
Lymphovascular invasion | ||||
Negative | 136 (72.3) | 32 | 78.3 | <0.001 |
Positive | 52 (27.7) | 29 | 45.6 | |
Perineural invasion | ||||
Negative | 161 (85.6) | 44 | 74.1 | <0.001 |
Positive | 27 (14.4) | 17 | 40.1 | |
Lymph node involvement | ||||
Negative | 98 (54.4) | 23 | 78.8 | 0.005 |
Positive | 82 (45.6) | 35 | 58.5 |
Abbreviations: CEA, carcinoembryonic antigen; IQR, interquartile range.
*Column subtotals do not sum to N of patients and N of deaths due to missing data.
†P values were calculated using the log-rank test.
‡According to the American Joint Committee on Cancer - Cancer Staging Manual (version 6.0).
P < 0.05 are in boldface.